Rezolut and CureMetrix have launched a pilot program in New York City to improve breast cancer detection in women receiving routine screening mammograms.
Rezolut's diagnostic medical imaging platform will incorporate CureMetrix's artificial intelligence software for screening mammography exams.
The two firms expect results of the pilot program to show that the partnership can result in better mammography workflow and improved performance metrics such as increased cancer detection rates and fewer false positives, they said.
